[Antiestrogens (tamoxifen) in the alternative therapy of benign prostatic hyperplasia]

In a non-randomized study the authors administered Tamoxifen to 17 patients with benign prostate hyperplasia who met the criteria for administration of the drug. In the group of patients no significant change of symptoms according to Goldenberg's score was recorded nor changes of prostate size and postmiction residues. In uroflowmetry the significant change of values of maximum flow (p < 0.05) was not associated with a change in the mean flow. The authors assume that monotherapy with Tamoxifen is not effective enough and recommended administration of antioestrogen only in combination with other drugs.